董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| R. John Fletcher | 男 | Chairman of the Board | 80 | 14.00万美元 | 22.68 | 2026-03-12 |
| Joseph M. Manko, Jr. | 男 | Independent Director | 60 | 11.58万美元 | 584.85 | 2026-03-12 |
| Robert A. Casella | -- | Independent Director | -- | 12.50万美元 | 未持股 | 2026-03-12 |
| Shahriar Matin | -- | Independent Director | -- | 11.58万美元 | 9.76 | 2026-03-12 |
| Donna French | -- | Independent Director | -- | 11.00万美元 | 9.49 | 2026-03-12 |
| Edward Wholihan | -- | Independent Director | -- | 11.00万美元 | 4.77 | 2026-03-12 |
| Linda Tharby | 女 | President, Chief Executive Officer, Director | 57 | 173.79万美元 | 119.28 | 2026-03-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Christopher Pazdan | 男 | Chief Operating Officer | 43 | 未披露 | 未持股 | 2026-03-12 |
| Adam Kalbermatten | 男 | Chief Commercial Officer | 42 | 257.04万美元 | 30.00 | 2026-03-12 |
| Eric Schiller | 男 | Chief Technology Officer | 52 | 未披露 | 7.64 | 2026-03-12 |
| Linda Tharby | 女 | President, Chief Executive Officer, Director | 57 | 173.79万美元 | 119.28 | 2026-03-12 |
| Tom Adams | 男 | Chief Financial Officer, Secretary and Treasurer | 53 | 93.93万美元 | 未持股 | 2026-03-12 |
董事简历
中英对照 | 中文 | 英文- R. John Fletcher
-
R. John Fletcher目前担任Fletcher Spaght Inc.（他于1983年创立的战略咨询和风险投资公司）的首席执行官和董事总经理。他于2002年加入上市医疗设备公司Spectranetics Corporation的董事会，并于2010年至2017年担任董事会主席。由于他在Spectranetics的工作，Fletcher先生被National Association of Corporate Directors NACD任命为2018年的年度董事。他目前任职于Axcelis Corporation, MRI Interventions, Inc.的董事会，以及Metabolon, Inc.的董事长。他是Dartmouth College，Thayer School of Engineering /Tuck School of Business的企业合作委员会名誉主席，Beth Israel Deaconess Medical Center和麻省理工学院（MIT） Whitehead Institute的顾问委员会成员。他持有Southern Illinois University的工商管理硕士学位和George Washington University的市场营销工商管理硕士学位。
R. John Fletcher currently serves as CEO and Managing Director of Fletcher Spaght Inc., a strategy consulting and venture capital firm which he founded in 1983. Mr. Fletcher joined the Board of Directors of publicly-traded medical device company Spectranetics Corporation in 2002 and served as Chairman of the Board from 2010-2017. Mr. Fletcher was named 2018 Director of the Year by The National Association of Corporate Directors NACD for his work at Spectranetics. Mr. Fletcher currently serves on the Board of Directors of Axcelis Corporation, MRI Interventions, Inc and is Chairman of Metabolon, Inc. He is Chairman Emeritus of the Corporate Collaboration Council at the Thayer School of Engineering/Tuck School of Business at Dartmouth College and serves on the Board of Advisors of Beth Israel Deaconess Medical Center and the Whitehead Institute at MIT. Mr. Fletcher received his MBA from Southern Illinois University and a BBA in Marketing from George Washington University. - R. John Fletcher目前担任Fletcher Spaght Inc.（他于1983年创立的战略咨询和风险投资公司）的首席执行官和董事总经理。他于2002年加入上市医疗设备公司Spectranetics Corporation的董事会，并于2010年至2017年担任董事会主席。由于他在Spectranetics的工作，Fletcher先生被National Association of Corporate Directors NACD任命为2018年的年度董事。他目前任职于Axcelis Corporation, MRI Interventions, Inc.的董事会，以及Metabolon, Inc.的董事长。他是Dartmouth College，Thayer School of Engineering /Tuck School of Business的企业合作委员会名誉主席，Beth Israel Deaconess Medical Center和麻省理工学院（MIT） Whitehead Institute的顾问委员会成员。他持有Southern Illinois University的工商管理硕士学位和George Washington University的市场营销工商管理硕士学位。
- R. John Fletcher currently serves as CEO and Managing Director of Fletcher Spaght Inc., a strategy consulting and venture capital firm which he founded in 1983. Mr. Fletcher joined the Board of Directors of publicly-traded medical device company Spectranetics Corporation in 2002 and served as Chairman of the Board from 2010-2017. Mr. Fletcher was named 2018 Director of the Year by The National Association of Corporate Directors NACD for his work at Spectranetics. Mr. Fletcher currently serves on the Board of Directors of Axcelis Corporation, MRI Interventions, Inc and is Chairman of Metabolon, Inc. He is Chairman Emeritus of the Corporate Collaboration Council at the Thayer School of Engineering/Tuck School of Business at Dartmouth College and serves on the Board of Advisors of Beth Israel Deaconess Medical Center and the Whitehead Institute at MIT. Mr. Fletcher received his MBA from Southern Illinois University and a BBA in Marketing from George Washington University.
- Joseph M. Manko, Jr.
-
JosephM.Manko，Jr.自2013年以来一直担任Horton Capital Management LLC的高级负责人，Horton Capital Partners Fund，LP“Horton Fund”的投资经理。霍顿基金是该公司的重要股东。Manko先生在资产管理、投资银行、私募股权和企业证券市场拥有超过20年的投资经验。从2005年到2010年，他曾担任BZ Fund Management Limited（位于瑞士）的合伙人兼首席执行官，在那里他曾负责公司财务、私人股本投资、三个公共股本基金和公司的特殊情况和事件驱动战略。在此之前，Manko先生是伦敦Deutsche Bank的董事总经理。他的投资银行生涯始于美林证券（Merrill Lynch），担任香港Vice President，在此之前，Manko先生是Skadden，Arps，Slate，Meagher&Flom LLP的公司财务律师。Manko先生曾在生物制药行业的几家公司的董事会任职，并为制药、生物技术和医疗技术行业的许多公司提供建议，目前担任SafeguardScientifics，Inc.、Wireless TelecomGroup，Inc.和CreativeRealities，Inc.的董事。Manko先生在宾夕法尼亚大学（University of Pennsylvania）获得学士学位和法学博士学位。
Joseph M. Manko, Jr. has been the Senior Principal in Horton Capital Management LLC, the investment manager for the Horton Capital Partners Fund, LP "Horton Fund" since 2013. The Horton Fund is a significant shareholder in the Company. Mr. Manko has over 20 years of investment experience in the asset management, investment banking, private equity and corporate securities markets. From 2005 to 2010 Mr. Manko was a Partner and Chief Executive Officer of Switzerland-based BZ Fund Management Limited, where he was responsible for corporate finance, private equity investments, three public equity funds and the firm's Special Situations and Event-Driven strategies. Prior to that Mr. Manko was a Managing Director with Deutsche Bank in London. He began his investment banking career at Merrill Lynch as a Vice President in Hong Kong and prior to that, Mr. Manko was a corporate finance attorney at Skadden, Arps, Slate, Meagher & Flom LLP. Mr. Manko has served on the board of several companies in the bio-pharmaceutical industry and has advised numerous companies in the pharmaceutical, biotech and medtech industries and currently serves as a director of Safeguard Scientifics, Inc., Wireless Telecom Group, Inc., and Creative Realities, Inc. Mr. Manko earned both his B.A. and Juris Doctor from the University of Pennsylvania. - JosephM.Manko，Jr.自2013年以来一直担任Horton Capital Management LLC的高级负责人，Horton Capital Partners Fund，LP“Horton Fund”的投资经理。霍顿基金是该公司的重要股东。Manko先生在资产管理、投资银行、私募股权和企业证券市场拥有超过20年的投资经验。从2005年到2010年，他曾担任BZ Fund Management Limited（位于瑞士）的合伙人兼首席执行官，在那里他曾负责公司财务、私人股本投资、三个公共股本基金和公司的特殊情况和事件驱动战略。在此之前，Manko先生是伦敦Deutsche Bank的董事总经理。他的投资银行生涯始于美林证券（Merrill Lynch），担任香港Vice President，在此之前，Manko先生是Skadden，Arps，Slate，Meagher&Flom LLP的公司财务律师。Manko先生曾在生物制药行业的几家公司的董事会任职，并为制药、生物技术和医疗技术行业的许多公司提供建议，目前担任SafeguardScientifics，Inc.、Wireless TelecomGroup，Inc.和CreativeRealities，Inc.的董事。Manko先生在宾夕法尼亚大学（University of Pennsylvania）获得学士学位和法学博士学位。
- Joseph M. Manko, Jr. has been the Senior Principal in Horton Capital Management LLC, the investment manager for the Horton Capital Partners Fund, LP "Horton Fund" since 2013. The Horton Fund is a significant shareholder in the Company. Mr. Manko has over 20 years of investment experience in the asset management, investment banking, private equity and corporate securities markets. From 2005 to 2010 Mr. Manko was a Partner and Chief Executive Officer of Switzerland-based BZ Fund Management Limited, where he was responsible for corporate finance, private equity investments, three public equity funds and the firm's Special Situations and Event-Driven strategies. Prior to that Mr. Manko was a Managing Director with Deutsche Bank in London. He began his investment banking career at Merrill Lynch as a Vice President in Hong Kong and prior to that, Mr. Manko was a corporate finance attorney at Skadden, Arps, Slate, Meagher & Flom LLP. Mr. Manko has served on the board of several companies in the bio-pharmaceutical industry and has advised numerous companies in the pharmaceutical, biotech and medtech industries and currently serves as a director of Safeguard Scientifics, Inc., Wireless Telecom Group, Inc., and Creative Realities, Inc. Mr. Manko earned both his B.A. and Juris Doctor from the University of Pennsylvania.
- Robert A. Casella
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Shahriar Matin
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Donna French
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Edward Wholihan
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Linda Tharby
-
Linda Tharby于2021年4月被任命为总裁兼首席执行官。Tharby女士拥有超过25年的行政领导经验，建立和领导表现出色的全球性组织，开发和商业化产品和服务创新，同时在家庭环境中为患者提供解决方案。在加入KORU之前，Tharby女士在过去24年里在Becton Dickinson（“BD”）担任各种职务，承担更多的责任。塔比是BD执行领导团队的成员，该团队将公司从一家价值80亿美元的医疗用公司转变为一家价值180亿美元的全球医疗技术公司。塔比上一次担任首席客户体验官是从2018年7月到2020年12月。在此之前，她曾于2016年10月至2018年7月担任BD首席人力资源官。从1998年到2016年，她在BD担任过多个高级全球业务领导职务，包括执行副总裁兼生命科学总裁、预分析系统和生物科学集团总裁、糖尿病护理全球总裁和制药系统副总裁/总经理。Tharby女士拥有Ontario Canada滑铁卢Wilfrid Laurier大学工商管理荣誉学士学位。
Linda Tharby was appointed as President and CEO in April 2021. Ms. Tharby has over 25 years of executive leadership experience building and leading strong performing global organizations that develop and commercialize products and service innovations, while delivering solutions to patients in the home setting. Prior to joining KORU, Ms. Tharby spent 24 years working in vario roles of increased responsibility at Becton Dickinson ("BD"). Ms. Tharby was a member of the Executive Leadership team of BD that transformed the company from an $8 billion medical supplies company to an $18 billion global medical technology company. Ms. Tharby's last role at BD was as Chief Ctomer Experience Officer from July 2018 through December 2020. Prior to that she served as BD's Chief Human Resces Officer, from October 2016 through July 2018. From 1998 to 2016, she held numero senior global biness leadership roles at BD, including Executive Vice President and President of Life Sciences, Group President of Pre Analytical Systems and Biosciences, Worldwide President of Diabetes Care, and Vice President/General Manager of Pharmaceutical Systems. Ms. Tharby has an Honors Bachelor of Biness Administration from Wilfrid Laurier University in Waterloo, Ontario, Canada. - Linda Tharby于2021年4月被任命为总裁兼首席执行官。Tharby女士拥有超过25年的行政领导经验，建立和领导表现出色的全球性组织，开发和商业化产品和服务创新，同时在家庭环境中为患者提供解决方案。在加入KORU之前，Tharby女士在过去24年里在Becton Dickinson（“BD”）担任各种职务，承担更多的责任。塔比是BD执行领导团队的成员，该团队将公司从一家价值80亿美元的医疗用公司转变为一家价值180亿美元的全球医疗技术公司。塔比上一次担任首席客户体验官是从2018年7月到2020年12月。在此之前，她曾于2016年10月至2018年7月担任BD首席人力资源官。从1998年到2016年，她在BD担任过多个高级全球业务领导职务，包括执行副总裁兼生命科学总裁、预分析系统和生物科学集团总裁、糖尿病护理全球总裁和制药系统副总裁/总经理。Tharby女士拥有Ontario Canada滑铁卢Wilfrid Laurier大学工商管理荣誉学士学位。
- Linda Tharby was appointed as President and CEO in April 2021. Ms. Tharby has over 25 years of executive leadership experience building and leading strong performing global organizations that develop and commercialize products and service innovations, while delivering solutions to patients in the home setting. Prior to joining KORU, Ms. Tharby spent 24 years working in vario roles of increased responsibility at Becton Dickinson ("BD"). Ms. Tharby was a member of the Executive Leadership team of BD that transformed the company from an $8 billion medical supplies company to an $18 billion global medical technology company. Ms. Tharby's last role at BD was as Chief Ctomer Experience Officer from July 2018 through December 2020. Prior to that she served as BD's Chief Human Resces Officer, from October 2016 through July 2018. From 1998 to 2016, she held numero senior global biness leadership roles at BD, including Executive Vice President and President of Life Sciences, Group President of Pre Analytical Systems and Biosciences, Worldwide President of Diabetes Care, and Vice President/General Manager of Pharmaceutical Systems. Ms. Tharby has an Honors Bachelor of Biness Administration from Wilfrid Laurier University in Waterloo, Ontario, Canada.
高管简历
中英对照 | 中文 | 英文- Christopher Pazdan
Christopher Pazdan于2021年9月加入KORU医疗，担任质量保证和监管事务副总裁，之后于2022年晋升为运营高级副总裁，随后于2024年7月晋升为首席运营官。作为首席运营官，Pazdan先生负责监督制造、Scing、供应链、质量、监管和项目管理。在加入KORU之前，Pazdan先生在医疗器械工业的vario职能部门工作了17年，最近担任Hillrom质量保证副总裁。在担任这一职务期间，帕兹丹曾担任多个Biness部门的质量主管，该部门的年收入为20亿美元。Pazdan先生在伊利诺伊大学厄巴纳香槟分校获得工程学理学学士学位。
Christopher Pazdan joined KORU Medical in September 2021 as Vice President of Quality Assurance and Regulatory Affairs before being promoted to Senior Vice President of Operations in 2022, and subsequently to Chief Operating Officer in July 2024. As Chief Operating Officer, Mr. Pazdan oversees Manufacturing, Scing, Supply Chain, Quality, Regulatory and Project Management. Prior to joining KORU, Mr. Pazdan spent 17 years in vario functions within the Medical Device industry, most recently serving as Vice President of Quality Assurance at Hillrom. In this role, Mr. Pazdan was head of quality for multiple biness segments comprising $2 billion in annual revenue. Mr. Pazdan earned his Bachelor of Science in Engineering from the University of Illinois Urbana Champaign.- Christopher Pazdan于2021年9月加入KORU医疗，担任质量保证和监管事务副总裁，之后于2022年晋升为运营高级副总裁，随后于2024年7月晋升为首席运营官。作为首席运营官，Pazdan先生负责监督制造、Scing、供应链、质量、监管和项目管理。在加入KORU之前，Pazdan先生在医疗器械工业的vario职能部门工作了17年，最近担任Hillrom质量保证副总裁。在担任这一职务期间，帕兹丹曾担任多个Biness部门的质量主管，该部门的年收入为20亿美元。Pazdan先生在伊利诺伊大学厄巴纳香槟分校获得工程学理学学士学位。
- Christopher Pazdan joined KORU Medical in September 2021 as Vice President of Quality Assurance and Regulatory Affairs before being promoted to Senior Vice President of Operations in 2022, and subsequently to Chief Operating Officer in July 2024. As Chief Operating Officer, Mr. Pazdan oversees Manufacturing, Scing, Supply Chain, Quality, Regulatory and Project Management. Prior to joining KORU, Mr. Pazdan spent 17 years in vario functions within the Medical Device industry, most recently serving as Vice President of Quality Assurance at Hillrom. In this role, Mr. Pazdan was head of quality for multiple biness segments comprising $2 billion in annual revenue. Mr. Pazdan earned his Bachelor of Science in Engineering from the University of Illinois Urbana Champaign.
- Adam Kalbermatten
Adam Kalbermatten于2025年7月加入Koru Medical Systems，担任首席商务官，在医疗设备和制药行业带来了20多年的商业领导经验。Adam在加速增长、扩展binesses和建立高绩效团队方面有着良好的记录，同时提供创新的、以CTomer为中心的解决方案。在加入Koru之前，Adam曾在Becton Dickinson（“BD”）担任高级药物输送系统BINES副总裁兼总经理，直至2025年。He previoly曾担任ZebraSci的首席执行官，ZebraSci是一家药物装置组合产品开发公司，beten 20192022，在那里他领导了一项成功的扭亏为盈和增长战略，导致该公司被BD收购。在其职业生涯的早期，亚当曾在Terumo Corporation和BD Beten担任全球领导和工程职务，2005年和2019年。Adam拥有史蒂文斯理工学院机械工程学学士学位和工程管理工程学硕士学位，以及哥伦比亚BINCE学校MBA学位。
Adam Kalbermatten joined Koru Medical Systems as Chief Commercial Officer in July 2025. Adam has a proven track record of accelerating growth, scaling binesses, and building high performing teams, all while delivering innovative, ctomer centric solutions. Prior to Koru, Adam served as Vice President and General Manager of the Advanced Drug Delivery Systems biness at Becton Dickinson ("BD") until 2025. He previoly served as Chief Executive Officer of ZebraSci, a drug device combination product development firm, beten 2019 2022, where he led a successful turnaround and growth strategy, resulting in the company's acquisition by BD. Earlier in his career, Adam held global leadership and engineering roles at both Terumo Corporation and BD beten 2005 and 2019. Adam holds a Bachelor of Engineering in Mechanical Engineering and a Master of Engineering in Engineering Management from Stevens Institute of Technology and an MBA from Columbia Biness School.- Adam Kalbermatten于2025年7月加入Koru Medical Systems，担任首席商务官，在医疗设备和制药行业带来了20多年的商业领导经验。Adam在加速增长、扩展binesses和建立高绩效团队方面有着良好的记录，同时提供创新的、以CTomer为中心的解决方案。在加入Koru之前，Adam曾在Becton Dickinson（“BD”）担任高级药物输送系统BINES副总裁兼总经理，直至2025年。He previoly曾担任ZebraSci的首席执行官，ZebraSci是一家药物装置组合产品开发公司，beten 20192022，在那里他领导了一项成功的扭亏为盈和增长战略，导致该公司被BD收购。在其职业生涯的早期，亚当曾在Terumo Corporation和BD Beten担任全球领导和工程职务，2005年和2019年。Adam拥有史蒂文斯理工学院机械工程学学士学位和工程管理工程学硕士学位，以及哥伦比亚BINCE学校MBA学位。
- Adam Kalbermatten joined Koru Medical Systems as Chief Commercial Officer in July 2025. Adam has a proven track record of accelerating growth, scaling binesses, and building high performing teams, all while delivering innovative, ctomer centric solutions. Prior to Koru, Adam served as Vice President and General Manager of the Advanced Drug Delivery Systems biness at Becton Dickinson ("BD") until 2025. He previoly served as Chief Executive Officer of ZebraSci, a drug device combination product development firm, beten 2019 2022, where he led a successful turnaround and growth strategy, resulting in the company's acquisition by BD. Earlier in his career, Adam held global leadership and engineering roles at both Terumo Corporation and BD beten 2005 and 2019. Adam holds a Bachelor of Engineering in Mechanical Engineering and a Master of Engineering in Engineering Management from Stevens Institute of Technology and an MBA from Columbia Biness School.
- Eric Schiller
Eric Schiller于2025年12月加入Koru Medical Systems担任首席技术官，带来了超过25年的医疗器械和药物器械组合产品经验。他在产品开发、工程、供应链和生命周期管理方面拥有深厚的专业知识。在加入Koru之前，Eric在赛诺菲 Beten 2021和2025年担任高级领导职务，最近担任设备开发组合的全球主管，负责监管涵盖专科护理、普通医学和疫苗的80多项管道资产，到2030年计划推出约40项。在他职业生涯的早期，埃里克曾在百时美施贵宝、Celgene、Becton Dickinson和圣戈班担任领导职务，在那里他领导了全球商业化努力和先进的创新药物递送技术。Eric拥有Seton Hall大学MBA学位和新泽西理工学院机械工程学理学学士学位，是多项美国专利的指定发明人。
Eric Schiller joined Koru Medical Systems as Chief Technology Officer in December 2025. He has deep expertise across product development, engineering, supply chain, and lifecycle management. Prior to joining Koru, Eric held senior leadership roles at Sanofi beten 2021 and 2025, most recently serving as Global Head of Device Development Portfolio, where he oversaw more than 80 pipeline assets across Specialty Care, General Medicine, and Vaccines, with approximately 40 planned launches by 2030. Earlier in his career, Eric held leadership positions at Bristol Myers Squibb, Celgene, Becton Dickinson, and Saint Gobain, where he led global commercialization efforts and advanced innovative drug delivery technologies. Eric holds an MBA from Seton Hall University and a Bachelor of Science in Mechanical Engineering from the New Jersey Institute of Technology and is a named inventor on multiple U.S. patents.- Eric Schiller于2025年12月加入Koru Medical Systems担任首席技术官，带来了超过25年的医疗器械和药物器械组合产品经验。他在产品开发、工程、供应链和生命周期管理方面拥有深厚的专业知识。在加入Koru之前，Eric在赛诺菲 Beten 2021和2025年担任高级领导职务，最近担任设备开发组合的全球主管，负责监管涵盖专科护理、普通医学和疫苗的80多项管道资产，到2030年计划推出约40项。在他职业生涯的早期，埃里克曾在百时美施贵宝、Celgene、Becton Dickinson和圣戈班担任领导职务，在那里他领导了全球商业化努力和先进的创新药物递送技术。Eric拥有Seton Hall大学MBA学位和新泽西理工学院机械工程学理学学士学位，是多项美国专利的指定发明人。
- Eric Schiller joined Koru Medical Systems as Chief Technology Officer in December 2025. He has deep expertise across product development, engineering, supply chain, and lifecycle management. Prior to joining Koru, Eric held senior leadership roles at Sanofi beten 2021 and 2025, most recently serving as Global Head of Device Development Portfolio, where he oversaw more than 80 pipeline assets across Specialty Care, General Medicine, and Vaccines, with approximately 40 planned launches by 2030. Earlier in his career, Eric held leadership positions at Bristol Myers Squibb, Celgene, Becton Dickinson, and Saint Gobain, where he led global commercialization efforts and advanced innovative drug delivery technologies. Eric holds an MBA from Seton Hall University and a Bachelor of Science in Mechanical Engineering from the New Jersey Institute of Technology and is a named inventor on multiple U.S. patents.
- Linda Tharby
Linda Tharby于2021年4月被任命为总裁兼首席执行官。Tharby女士拥有超过25年的行政领导经验，建立和领导表现出色的全球性组织，开发和商业化产品和服务创新，同时在家庭环境中为患者提供解决方案。在加入KORU之前，Tharby女士在过去24年里在Becton Dickinson（“BD”）担任各种职务，承担更多的责任。塔比是BD执行领导团队的成员，该团队将公司从一家价值80亿美元的医疗用品公司转变为一家价值180亿美元的全球医疗技术公司。塔比上一次担任首席客户体验官是从2018年7月到2020年12月。在此之前，她曾于2016年10月至2018年7月担任BD首席人力资源官。从1998年到2016年，她在BD担任过多个高级全球业务领导职务，包括执行副总裁兼生命科学总裁、预分析系统和生物科学集团总裁、糖尿病护理全球总裁和制药系统副总裁/总经理。Tharby女士拥有Ontario Canada滑铁卢Wilfrid Laurier大学工商管理荣誉学士学位。
Linda Tharby was appointed as President and CEO in April 2021. Ms. Tharby has over 25 years of executive leadership experience building and leading strong performing global organizations that develop and commercialize products and service innovations, while delivering solutions to patients in the home setting. Prior to joining KORU, Ms. Tharby spent 24 years working in vario roles of increased responsibility at Becton Dickinson ("BD"). Ms. Tharby was a member of the Executive Leadership team of BD that transformed the company from an $8 billion medical supplies company to an $18 billion global medical technology company. Ms. Tharby's last role at BD was as Chief Ctomer Experience Officer from July 2018 through December 2020. Prior to that she served as BD's Chief Human Resces Officer, from October 2016 through July 2018. From 1998 to 2016, she held numero senior global biness leadership roles at BD, including Executive Vice President and President of Life Sciences, Group President of Pre Analytical Systems and Biosciences, Worldwide President of Diabetes Care, and Vice President/General Manager of Pharmaceutical Systems. Ms. Tharby has an Honors Bachelor of Biness Administration from Wilfrid Laurier University in Waterloo, Ontario, Canada.- Linda Tharby于2021年4月被任命为总裁兼首席执行官。Tharby女士拥有超过25年的行政领导经验，建立和领导表现出色的全球性组织，开发和商业化产品和服务创新，同时在家庭环境中为患者提供解决方案。在加入KORU之前，Tharby女士在过去24年里在Becton Dickinson（“BD”）担任各种职务，承担更多的责任。塔比是BD执行领导团队的成员，该团队将公司从一家价值80亿美元的医疗用品公司转变为一家价值180亿美元的全球医疗技术公司。塔比上一次担任首席客户体验官是从2018年7月到2020年12月。在此之前，她曾于2016年10月至2018年7月担任BD首席人力资源官。从1998年到2016年，她在BD担任过多个高级全球业务领导职务，包括执行副总裁兼生命科学总裁、预分析系统和生物科学集团总裁、糖尿病护理全球总裁和制药系统副总裁/总经理。Tharby女士拥有Ontario Canada滑铁卢Wilfrid Laurier大学工商管理荣誉学士学位。
- Linda Tharby was appointed as President and CEO in April 2021. Ms. Tharby has over 25 years of executive leadership experience building and leading strong performing global organizations that develop and commercialize products and service innovations, while delivering solutions to patients in the home setting. Prior to joining KORU, Ms. Tharby spent 24 years working in vario roles of increased responsibility at Becton Dickinson ("BD"). Ms. Tharby was a member of the Executive Leadership team of BD that transformed the company from an $8 billion medical supplies company to an $18 billion global medical technology company. Ms. Tharby's last role at BD was as Chief Ctomer Experience Officer from July 2018 through December 2020. Prior to that she served as BD's Chief Human Resces Officer, from October 2016 through July 2018. From 1998 to 2016, she held numero senior global biness leadership roles at BD, including Executive Vice President and President of Life Sciences, Group President of Pre Analytical Systems and Biosciences, Worldwide President of Diabetes Care, and Vice President/General Manager of Pharmaceutical Systems. Ms. Tharby has an Honors Bachelor of Biness Administration from Wilfrid Laurier University in Waterloo, Ontario, Canada.
- Tom Adams
汤姆亚当斯于2021年11月加入KORU医疗系统，担任财务规划和分析副总裁，并于2022年7月被任命为临时首席财务官。亚当斯先生在财务规划、企业融资、商业和供应链融资以及并购（M & A）方面拥有广泛的背景。在加入KORU之前，Adams先生在Integra生命科学公司工作了10年，担任财务和会计控制方面的多个领导职位，最近的职位是财务高级总监。在这个职位上，亚当斯是Integra组织技术业务的财务主管，他在支持一个5亿美元的业务部门实现高增长和盈利方面发挥了领导作用。亚当斯曾担任集团财务总监/FP & A全球供应主管，在加入Integra生命科学公司之前，他曾在辉瑞公司担任财务总监，担任过许多国内和国际职务。亚当斯先生在俄亥俄州立大学获得了商业管理-会计和金融理学学士学位。
Tom Adams joined KORU Medical in November 2021 as Vice President of Financial Planning and Analysis, was appointed Interim Chief Financial Officer in July 2022 and Chief Financial Officer in Augt 2023. Mr. Adams has an extensive background in financial planning, corporate finance, commercial and supply chain finance, and mergers and acquisitions (M&A). Prior to joining KORU Medical, Mr. Adams spent 10 years at Integra Life Sciences in vario leadership positions in Finance and Accounting Controllership with his most recent position as Senior Director of Finance. In this role, Mr. Adams was the head of finance for Integra's Tissue Technology Biness where he served a leading role in supporting a $500 million biness unit to high growth and profitability. Previo roles included Group Controller/Head of FP&A Global Supply and prior to Integra Life Sciences, Mr. Adams served as Director of Finance at Pfizer Inc serving in many domestic and international roles. Mr. Adams earned his Bachelor of Science in Biness Administration Accounting & Finance from the Ohio State University.- 汤姆亚当斯于2021年11月加入KORU医疗系统，担任财务规划和分析副总裁，并于2022年7月被任命为临时首席财务官。亚当斯先生在财务规划、企业融资、商业和供应链融资以及并购（M & A）方面拥有广泛的背景。在加入KORU之前，Adams先生在Integra生命科学公司工作了10年，担任财务和会计控制方面的多个领导职位，最近的职位是财务高级总监。在这个职位上，亚当斯是Integra组织技术业务的财务主管，他在支持一个5亿美元的业务部门实现高增长和盈利方面发挥了领导作用。亚当斯曾担任集团财务总监/FP & A全球供应主管，在加入Integra生命科学公司之前，他曾在辉瑞公司担任财务总监，担任过许多国内和国际职务。亚当斯先生在俄亥俄州立大学获得了商业管理-会计和金融理学学士学位。
- Tom Adams joined KORU Medical in November 2021 as Vice President of Financial Planning and Analysis, was appointed Interim Chief Financial Officer in July 2022 and Chief Financial Officer in Augt 2023. Mr. Adams has an extensive background in financial planning, corporate finance, commercial and supply chain finance, and mergers and acquisitions (M&A). Prior to joining KORU Medical, Mr. Adams spent 10 years at Integra Life Sciences in vario leadership positions in Finance and Accounting Controllership with his most recent position as Senior Director of Finance. In this role, Mr. Adams was the head of finance for Integra's Tissue Technology Biness where he served a leading role in supporting a $500 million biness unit to high growth and profitability. Previo roles included Group Controller/Head of FP&A Global Supply and prior to Integra Life Sciences, Mr. Adams served as Director of Finance at Pfizer Inc serving in many domestic and international roles. Mr. Adams earned his Bachelor of Science in Biness Administration Accounting & Finance from the Ohio State University.